In a nutshell This study aimed to investigate the long-term safety and effectiveness of low-dose pegylated (PEG) interferon-α (IFN-α) combined with dasatinib in patients with chronic-phase (CP) chronic myeloid leukemia (CML). This study concluded that this treatment was safe and effective in the long-term in these...
Read More
In a nutshell This study described real-world outcomes for patients with chronic myeloid leukemia (CML) that started a second-generation tyrosine kinase inhibitor (TKI) therapy and needed to switch to an alternative TKI. The authors concluded that intolerance was the major reason to switch to an alternative TKI and that outcomes were very good...
Read More
In a nutshell This study aimed to investigate the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to tyrosine kinase inhibitor (TKI) treatment. This study concluded that...
Read More
In a nutshell This study aimed to compare dasatinib (Sprycel) and nilotinib (Tasigna) as second-line treatments for patients with chronic-phase (CP) chronic myeloid leukemia (CML) in a real-life setting. This study concluded that both dasatinib and nilotinib are equally effective and well...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of flumatinib (HHGV678) compared to imatinib (Gleevec) in patients with chronic-phase chronic myeloid leukemia. This study concluded that flumatinib was a safe and more effective than imatinib in these patients. Some background...
Read More
In a nutshell This study aimed to compare the effectiveness and safety of generic and branded imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. This study concluded that generic and branded imatinib had similar effectiveness and safety in these patients. Some...
Read MoreIn a nutshell This study aimed to investigate the outcome of early switching from imatinib to dasatinib of patients with chronic-phase chronic myeloid leukemia with weak responses to imatinib treatment. The study concluded that this switch may offer clinical benefit in certain patients. Some background Imatinib...
Read MoreIn a nutshell This study aimed to investigate if nilotinib was safe and effective as a long-term treatment in patients with chronic-phase chronic myeloid leukemia. This study concluded that nilotinib is safe and effective in the long-term in these patients. Some background Nilotinib...
Read More
In a nutshell The study evaluated if the molecular response to Imatinib (Gleevec) is a proper way to judge treatment progress in Iranian patients with chronic-phase chronic myeloid leukemia (CP-CML). The main finding was that survival was improved in patients who had a better molecular response to imatinib. Some background Patients with...
Read More
In a nutshell This study aimed to evaluate glucose (blood sugar) and lipid (fat) metabolism between dasatinib, nilotinib, and imatinib in patients with chronic-phase chronic myeloid leukemia. This study concluded that dasatinib and nilotinib had a negative impact on glucose and lipid...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of imatinib treatment in patients with newly diagnosed chronic myeloid leukemia. This study concluded that patients of lower weight and older age are more vulnerable to side effects. Some background Imatinib (Gleevec) is a targeted therapy...
Read More
In a nutshell This study investigated the prescribed doses of tyrosine kinase inhibitors (TKIs) and the outcomes of elderly patients with chronic myeloid leukemia (CML). The study concluded that the currently prescribed TKI dose might be higher than necessary in elderly patients. Some background TKIs such as imatinib (Glivec), dasatinib...
Read More
